Salamatu Abdul-Aziz Dr Nawaraj Bhattarai Professor Luke Vale Dr Gurdeep Sagoo Dr Asima Mukhopadhyay et al. | Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer | 2025 |
|
Dr Asima Mukhopadhyay
| Retraction note: Autophagy-independent induction of LC3B through oxidative stress reveals its non-canonical role in anoikis of ovarian cancer cells (Cell Death & Disease, (2018), 9, 10, (934), 10.1038/s41419-018-0989-8) | 2024 |
|
Dr Santu Saha Dr Stuart Rundle Dr Ioannis Kotsopoulos Dr Jake Begbie Rachel Howarth et al. | Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy | 2022 |
|
Hannah Smith Dr Elaine Willmore Dr Asima Mukhopadhyay Dr Yvette Drew Professor Nicola Curtin et al. | Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling | 2022 |
|
Dr Asima Mukhopadhyay
| Economic evaluation of population-based BRCA1/BRCA2 mutation testing across multiple countries and health systems | 2020 |
|
Dr Asima Mukhopadhyay Dr Yvette Drew Liz Matheson Dr Mo Salehan Lucy Gentles et al. | Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors | 2019 |
|
Lucy Gentles Bojidar Goranov Elizabeth Matheson Dr Ashleigh Herriott Dr Angelika Kaufmann et al. | Exploring the frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types | 2019 |
|
Dr Asima Mukhopadhyay
| Autophagy-independent induction of LC3B through oxidative stress reveals its non-canonical role in anoikis of ovarian cancer cells | 2018 |
|
Dr Ioannis Kotsopoulos Dr Asima Mukhopadhyay Professor John Lunec Professor Nicola Curtin Ali Kucukmetin et al. | IN VITRO SINGLE AGENT RUCAPARIB CYTOTOXICITY AND CISPLATIN CHEMO-POTENTIATION IN CERVICAL CANCER CELL LINES | 2016 |
|
Dr Ganiy Abdulrahman Elizabeth Matheson Dr Yvette Drew Professor Nicola Curtin Dr Asima Mukhopadhyay et al. | Investigating PARP inhibitor sensitisation by hyperthermia and HSP90 inhibition | 2016 |
|
Dr Rachel O'Donnell Dr Stuart Rundle Dr Ioannis Kotsopoulos Chun Ang Ali Kucukmetin et al. | Metastatic involvement of the lesser sac in advanced epithelial ovarian cancer | 2016 |
|
Dr Asima Mukhopadhyay
| Ovarian cysts and cancer in pregnancy | 2016 |
|
Dr Ioannis Kotsopoulos Ali Kucukmetin Dr Asima Mukhopadhyay Professor John Lunec Professor Nicola Curtin et al. | Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis Mechanism and Potential Role for PARP Inhibitors | 2016 |
|
Elizabeth Matheson Dr Mo Salehan Dr Asima Mukhopadhyay Professor Nicola Curtin Dr Yvette Drew et al. | Preclinical studies of the PARP inhibitor olaparib in combination with imatinib in BRCA stratified ovarian cancer | 2016 |
|
Dr Rachel O'Donnell Dr Stuart Rundle Dr Ioannis Kotsopoulos Chun Ang Ali Kucukmetin et al. | Risk factors for lesser sac metastasis in advanced ovarian cancer. | 2016 |
|
Dr Asima Mukhopadhyay Michelle Dixon Dr Evan Mulligan James Murray Professor Nicola Curtin et al. | Evaluation of different methods to assess homologous recombination status and sensitivity to parp inhibitors in ovarian cancer | 2014 |
|
Professor Richard Edmondson Dr Asima Mukhopadhyay Professor Nicola Curtin
| Molecular characterization of matched ovarian ascites and tumors suggests multiple mechanisms for a homologous recombination defective phenotype | 2014 |
|
Dr Rachel O'Donnell Dr Aiste McCormick Dr Asima Mukhopadhyay Michelle Dixon Dr Angelika Kaufmann et al. | The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis | 2014 |
|
Dr Rachel O'Donnell Laura Woodhouse Dr Aiste McCormick Dr Asima Mukhopadhyay Michelle Dixon et al. | Functional Intra-Tumour Heterogeneity in Ovarian Cancer: What is a Representative Tumour Sample? | 2013 |
|